Novamind

Press

Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults.1 The phase II…

Blog

PRO: A Deeper Dive Into The Numinus + Novamind Merger

Earlier this week, Numinus Wellness Inc. (NUMI) struck a deal to acquire Toronto-based Novamind (NM) for approximately $20.8 million, marking one the of largest mergers to date inside the public psychedelic sector. For the past couple of years, Novamind, which operates solely in the United States, has made significant advances toward establishing a stronghold in…

Novamind

Press

Novamind Partner to Acquire Specialized Ibogaine Group in Brazil

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, is pleased to report that its strategic partner, Bienstar Wellness Corp., has signed a letter of intent to acquire BRC Saude Mental E Terapias Assistidas Ltda., a leader in specialized ibogaine treatments for substance use disorder…